Ascletis’ Gannex reports positive interim PhII NASH data after scrapping previous mid-stage R&D plans

As­cle­tis’ sub­sidiary Gan­nex re­vealed that its non-al­co­holic steato­hep­ati­tis (NASH) drug can­di­date sig­nif­i­cant­ly re­duced av­er­age lev­els of liv­er fat in pa­tients en­rolled in a mid-stage tri­al, mark­ing a pos­i­tive mile­stone for the Chi­nese com­pa­ny.

Gan­nex’s Phase II study is in­ves­ti­gat­ing two dos­es of Gan­nex’s THR-be­ta ag­o­nist can­di­date ver­sus place­bo for 52 weeks and is ex­pect­ed to en­roll a to­tal of 180 NASH pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.